|
Jun 15
|
Berenberg Bank Maintains a Hold Rating on Novartis (NVS)
|
|
Jun 13
|
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
|
|
Jun 13
|
Novartis reports positive results from Phase IIIB study of iptacopan for PNH
|
|
Jun 12
|
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 10
|
Top Cancer Stocks to Supercharge Your 2025 Portfolio
|
|
Jun 10
|
The former Wall Street analyst shaping Novartis’ big-picture strategy
|
|
Jun 9
|
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
|
|
Jun 9
|
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
|
|
Jun 9
|
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
|
|
Apr 30
|
Why Novartis (NVS) is a Top Value Stock for the Long-Term
|
|
Apr 30
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Apr 30
|
Novartis to acquire Regulus in deal for kidney disease drug
|
|
Apr 30
|
Novartis to Acquire Regulus in $1.7 Billion Deal
|
|
Apr 30
|
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal
|
|
Apr 30
|
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
|
|
Apr 30
|
Novartis AG (NVS) Q1 2025 Earnings Call Highlights: Impressive Growth and Strategic Advancements
|
|
Apr 29
|
Novartis Scores A Beat-And-Raise Quarter — And Shares Make A Break For A Buy Point
|
|
Apr 29
|
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
|
|
Apr 29
|
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
|